PBKM granted 13.7 mln PLN funds from NCBiR to develop stem cell therapy for ALS

The National Center for Research and Development (NCBiR) in Poland has approved the request of PBKM (Polski Bank Komórek Macierzystych) for co-financing the project titled “Development of an Innovative Advanced Therapy Medicinal Product Based on Mesenchymal Stem Cells Derived from Wharton’s Jelly for the Treatment of Amyotrophic Lateral Sclerosis (ALS).” This funding, amounting to approximately 13.7 million PLN, will support the project’s total estimated cost of around 23.9 million PLN. The project represents a significant milestone in the advancement of cell-based therapies, focusing on the potential use of mesenchymal stem cells (MSCs) derived from the Wharton’s jelly of the umbilical cord in treating ALS, a progressive
and currently incurable neurodegenerative disease.

The financial support from NCBiR not only underscores the importance of this innovative research but also reflects Poland’s commitment to supporting cutting-edge biomedical advancements. This research project is an important step towards developing a novel therapeutic approach for ALS patients, leveraging the regenerative properties of stem cells. With this co-financing, PBKM aims to accelerate the development of this promising treatment, which could have a transformative impact on the lives of individuals suffering from ALS, offering hope for a future breakthrough in neurodegenerative disease therapies.

The funding was part of InnoNeuroPharm program, initiated by Poland’s NCBiR, aimed to enhance the competitiveness and innovation of the Polish pharmaceutical sector, particularly in neuromedicine. In its first competition, NCBiR allocated approximately 160 million PLN to support research and development projects in this field. Program funded projects focusing on:

Innovative medicinal products
Advanced manufacturing technologies
Novel diagnostic methods and biomarkers in neuromedicine
Innovative rehabilitation methods for neurological patients
Development of tools supporting research on medicinal products

Recently added

17 November 2025 FamiCord Group Recognized as Europe’s Leading Stem Cell Bank FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues. Read more
27 August 2025 Infantile cerebral palsy – Convincing evidence for the use of perinatal stem cells Leipzig, July 15, 2025 - Cerebral palsy (CP) continues to be one of the most common motor disabilities in childhood and is associated with permanent movement restrictions and spasticity. The therapeutic potential of stem cells from umbilical cord blood and tissue was discussed at the 37th Annual Meeting of the European Academy Of Childhood-onset Disabilities (EACD) and the 4th Meeting of the International Alliance of Academies of C hildhood Disability (IAACD) from June 24 - 28, 2025 in Heidelberg. As part of a symposium supported by FamiCord AG, international experts presented the current state of research and reported on the results from clinical practice. Read more